Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.
Type:
Grant
Filed:
October 22, 2018
Date of Patent:
February 14, 2023
Inventors:
Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber
Abstract: An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody. a pharmaceutical composition thereof and use thereof. Particularly, the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises a first protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically, relieve immunosuppression of CTLA4 and PD-1 on an organism specifically, activate T lymphocytes, and thus has good application prospects.
Abstract: The invention provides gastroenterological cancer determination methods that involve contacting a specimen, an antibody 1 that recognizes an ? chain of human haptoglobin, and an antibody 2 that recognizes a ? chain of human haptoglobin and does not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 1, or contacting the specimen and two antibodies selected from the antibodies 2 that recognize a ? chain of human haptoglobin and do not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 2. A determination is made based on the measurement of complex 1 or 2. Alternatively, the specimen and two antibodies selected from the antibodies 1 that recognize an ? chain of human haptoglobin are contacted to form a complex 3, and a determination is made by comparing the measurement results of complex 1 or 2 with complex 3.
Type:
Grant
Filed:
May 25, 2017
Date of Patent:
February 14, 2023
Assignees:
FUJIFILM WAKO PURE CHEMICAL CORPORATION, OSAKA UNIVERSITY
Abstract: Described herein are methods and compositions for the treatment of cancer. Aspects include administering (1) an agent that inhibits activity of a CBM signalosome complex, or (2) a cell engineered to have reduced CBM signalosome complex levels to a subject having cancer. In various embodiment, the methods further comprise administering second therapeutic, for example, a checkpoint inhibitor or anti-cancer therapy, to the subject.
Abstract: Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.
Type:
Grant
Filed:
July 9, 2019
Date of Patent:
February 7, 2023
Assignee:
University of Bern
Inventors:
Carsten Riether, Christian Schürch, Adrian Ochsenbein, Karen Silence
Abstract: Embodiments of the disclosure include methods and compositions for treatment of a medical condition related to the liver, including at least viral infections and liver cancer, for example. In specific embodiments, immunotherapies are provided for delivering polynucleotides locally to the liver, wherein the polynucleotides encode particular gene products that include bispecific antibodies, including those that target certain liver antigens, for example.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
January 31, 2023
Assignee:
BAYLOR COLLEGE OF MEDICINE
Inventors:
Robert Layne Kruse, Karl-Dimiter Bissig, Stephen M. G. Gottschalk, Thomas C. T. Shum
Abstract: Provided herein are methods and systems for the analysis of biomarkers, and methods of providing diagnoses and/or prognoses therewith. In particular, methods and systems for performing biomarker ratio imaging microscopy (BRIM) are provided, as well as methods of using BRIM for the analysis of biomarker pairs (e.g., CD44/CD24, N-cadherin/E-cadherin, CD74/CD59, etc.) diagnosis and/or prognosis of cancer (e.g., ductal carcinoma in situ).
Type:
Grant
Filed:
May 31, 2017
Date of Patent:
January 17, 2023
Assignee:
The Regents of the University of Michigan
Abstract: Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and/or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-L1 or PD-L2 by administering to the patient a nanoparticle composition and a PD-1 immunotherapy.
Type:
Grant
Filed:
August 31, 2017
Date of Patent:
January 10, 2023
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Abstract: Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the PI3K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the colon and other organs. The majority of mutations clustered near two positions within the PI3K helical or kinase domains. PIK3CA represents one of the most highly mutated oncogenes yet identified in human cancers and is useful as a diagnostic and therapeutic target.
Type:
Grant
Filed:
October 7, 2019
Date of Patent:
January 10, 2023
Assignee:
The Johns Hopkins University
Inventors:
Yardena Samuels, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein
Abstract: The present invention relates to compositions and methods for using a minibody. Minibodies described herein comprise a secretion signal, a variable heavy chain fragment, a variable light chain fragment, a constant chain fragment, and a hinge domain between the variable light chain fragment and the constant chain fragment. One aspect includes a nucleic acid encoding a minibody. Other aspects include compositions comprising a minibody and a modified T cell comprising a nucleic acid encoding a minibody. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy and treating a condition, such as cancer.
Type:
Grant
Filed:
March 23, 2017
Date of Patent:
January 10, 2023
Assignees:
Novartis AG, The Trustees of the University of Pennsylvania
Abstract: The present technology generally relates to methods and compositions relevant to the prediction that a subject with and/or after treatment for DCIS will experience a subsequent ipsilateral breast event that is a DCIS recurrence, an invasive breast cancer, both a DCIS recurrence and invasive cancer, or neither. The technology can assist one with how to treat such subjects.
Abstract: The clustered regularly interspaced short palindromic repeat (CRISPR) gene editing technique, based on the non-homologous end-joining (NHEJ) repair pathway, can efficiently generate gene knockouts of variably sizes. More precise genome editing, either the insertion or deletion of a desired fragment, can be done by combining the homology-directed-repair (HDR) pathway with CRISPR cleavage. HDR-mediated gene knock-in experiments are inefficient, with no reports of successful gene knock-in with DNA fragments larger than 4 kb. Targeted insertion of large DNA fragments (7.4 and 5.8 kb) into the genomes of mouse embryonic stem cells and zygotes, respectively, using the CRISPR/HDR technique without NHEJ inhibitors was performed and indicate that CRISPR/HDR without NHEJ inhibitors can result in highly efficient gene knock-in, equivalent to CRISPR/HDR with NHEJ inhibitors.
Type:
Grant
Filed:
September 30, 2019
Date of Patent:
December 20, 2022
Assignees:
University of South Florida, United States Department of Veterans Affairs
Abstract: Checkpoint regulator antagonists that bind specifically to TIGIT, PD-1 and/or PD-L1 are disclosed. Also disclosed are methods of making and using the checkpoint regulator inhibitors, including monospecific, bispecific and trispecific checkpoint regulator antagonists thereof.
Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
Type:
Grant
Filed:
October 2, 2019
Date of Patent:
December 6, 2022
Assignee:
Mersana Therapeutics, Inc.
Inventors:
Natalya D. Bodyak, Michael J. DeVit, Eric M. Krauland, Timothy B. Lowinger, Peter U. Park, Bianka Prinz, Aleksandr V. Yurkovetskiy
Abstract: Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.
Type:
Grant
Filed:
September 2, 2020
Date of Patent:
November 29, 2022
Assignee:
AFFIMED GMBH
Inventors:
Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Ellwanger, Uwe Reusch, Michael Damrat, Erich Rajkovic, Martin Treder
Abstract: Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.
Abstract: Certain universal neoepitopes and cancer specific neoepitopes and methods therefore are presented that may be used in immunotherapy and cancer diagnosis. Preferred therapeutic and diagnostic compositions include antibodies or fragments thereof that bind to neoepitopes on cancer cells.
Type:
Grant
Filed:
September 13, 2019
Date of Patent:
November 22, 2022
Assignee:
NantOmics, LLC
Inventors:
Stephen Charles Benz, Andrew Nguyen, Charles Joseph Vaske, John Zachary Sanborn
Abstract: An object of the present invention is to identify cancer antigen proteins specifically expressed on the surface of cancer cells and to provide a use of antibodies targeting such proteins as therapeutic and/or preventive agents for cancer. The present invention relates to, for example, a pharmaceutical composition for treatment and/or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids.
Abstract: A modular, small molecule regulated single chain variable fragment (scFv) fusion protein is disclosed. The scFv fusion protein comprises a ligand binding protein fused to a protein that binds to an exogenous control molecule, wherein the scFv fusion protein is directly regulated by the control molecule. Binding of the control molecule to the ligand binding protein induces a change in the affinity of the scFv for a target antigen. Methods of using the fusion protein to treat diseases such as cancer are also described.
Abstract: Provided herein are materials and methods for detecting colorectal neoplasms and colon cancer based on the expression levels of stool-derived eukaryotic RNA biomarkers in eukaryotic nucleic acid present in a stool sample from a subject, for example, a patient. The methods can be used for the detection of high-risk adenomas and colorectal neoplasm molecular subtypes.
Type:
Grant
Filed:
January 19, 2022
Date of Patent:
October 25, 2022
Assignee:
GENEOSCOPY, INC.
Inventors:
Andrew Barnell, Erica Barnell, Yiming Kang, Elizabeth Wurtzler, Katie Campbell